Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.5K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.5K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

6.7K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
6.7K
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

9.7K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical case of an inherited retinal disease with late manifestation].

Vestnik oftalmologii·2026
Same author

[Use of faricimab in neovascular age-related macular degeneration and diabetic macular edema in Russia. Results of the FARWATER retrospective study].

Vestnik oftalmologii·2025
Same author

[Artificial intelligence in assessment of individual risks of age-related macular degeneration progression].

Vestnik oftalmologii·2025
Same author

[Cognitive impairment and age-related eye pathology.]

Advances in gerontology = Uspekhi gerontologii·2025
Same author

[Management of patients with treatment-resistant neovascular age-related macular degeneration].

Vestnik oftalmologii·2024
Same author

[Faricimab: from research to clinical practice].

Vestnik oftalmologii·2023
Same journal

[Impairment of retinal and choroidal blood flow autoregulation in preeclampsia].

Vestnik oftalmologii·2026
Same journal

[Non-glaucomatous optic nerve atrophy: epidemiology, etiological structure, and clinical diagnostic features].

Vestnik oftalmologii·2026
Same journal

[Microbiota and microbiome of the lacrimal drainage system].

Vestnik oftalmologii·2026
Same journal

[Differential assessment of diagnostic signs of primary open-angle glaucoma and high myopia].

Vestnik oftalmologii·2026
Same journal

[Applied anatomy of the optic nerve].

Vestnik oftalmologii·2026
Same journal

[Epidemiology and diagnostic methods of microbial keratitis].

Vestnik oftalmologii·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss
07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

997

[Modern views on myopic maculopathy].

O A Zhabina1, E A Woods1, A A Plyukhova1

  • 1Research Institute of Eye Diseases, 11 A, B, Rossolimo St., Moscow, Russian Federation, 119021.

Vestnik Oftalmologii
|June 22, 2017
PubMed
Summary
This summary is machine-generated.

The growing incidence of myopia and complicated myopia poses a significant social challenge. Anti-VEGF therapy shows promise for treating myopic maculopathy-associated neovascularization, but requires systematic patient management.

Keywords:
anti-VEGF therapychoroidal neovascularizationintraocular pressuremyopiamyopic maculopathyranibizumabsubretinal neovascular membrane

More Related Videos

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.4K
Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients
07:06

Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients

Published on: March 29, 2022

3.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss
07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

997
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.4K
Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients
07:06

Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients

Published on: March 29, 2022

3.3K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Myopia Research

Context:

  • Myopia is a growing global health concern, with complicated myopia leading to disability in the working-age population.
  • Myopic maculopathy, a severe complication, significantly impacts vision and quality of life.
  • Understanding the etiology and classification of complicated myopia is crucial for effective management.

Purpose:

  • To review the current research on complicated myopia and myopic maculopathy.
  • To discuss the history, classification, and etiological factors of these conditions.
  • To evaluate treatment options for choroidal neovascularization (CNV) in myopic maculopathy, including anti-VEGF therapy and its complications.

Summary:

  • A comprehensive review of 61 sources on complicated myopia and myopic maculopathy was conducted.
  • Current knowledge gaps in myopic maculopathy necessitate advanced in vivo examination techniques for sclera and choroidea.
  • Anti-VEGF therapy is the most effective treatment for CNV in myopic maculopathy, though systematic patient selection and management protocols are still needed.

Impact:

  • Highlights the need for further research into scleral and choroidal examination for better understanding of myopic maculopathy.
  • Emphasizes the efficacy of anti-VEGF therapy in treating neovascular complications of myopia.
  • Stresses the importance of developing systematic approaches for patient selection and management in anti-VEGF therapy for myopic maculopathy.